Company intelligence / Profile preview
Ichnos Glenmark Innovation
New York, New York, United Statesiginnovate.com ↗
- Ownership
- Private
- Employees
- ~150
- Development stage
- Other
01
Overview
Lead programs are in Phase 1 clinical trials for various oncology indications. ISB 1442 (CD38 x CD47) and ISB 2001 (BCMA x CD38 x CD3) are advancing in early clinical development, with ISB 2001 recently licensed to AbbVie for further development in oncology and autoimmune indications. GRC 54276 (HPK1 inhibitor) is also in Phase 1.
- Therapeutic areas
- OncologyEndocrinologyDermatologyImmunology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyTrispecific monoclonal antibodySmall molecule
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
AbbVie
Beyond the preview
Go deeper on Ichnos Glenmark Innovation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ichnos Glenmark Innovation.